Allergy News and Research

RSS

The term allergy encompasses a wide range of conditions; it is not a disease in itself. In 1906 Clemens von Pirquet was the first to describe allergies as a changed or altered reaction of the immune system in response to exposure to foreign proteins. These days the term allergy – medically termed hypersensitivity, signifies an exaggerated reaction to foreign substances.

Combination drug to limit the dangerous side effects of morphine

University of Michigan scientists have developed a combination drug that promises a safer, more precise way for medics and fellow soldiers in battle situations to give a fallen soldier both morphine and a drug that limits morphine's dangerous side effects.

25 Sep 2009

La Jolla Institute scientist Hilde Cheroutre earns the 2009 NIH Director's Pioneer Award

A scientist at the La Jolla Institute for Allergy & Immunology has received one of the National Institutes of Health (NIH)'s top awards -- the 2009 NIH Director's Pioneer Award. The prestigious prize carries with it funding for total costs of up to $4.7 million over five years, and is designed to support the work of exceptionally creative scientists, whose novel proposals offer the potential to make extraordinary contributions to human health.

24 Sep 2009

MicroDose initiates Phase 1 clinical trial investigating the pharmacokinetics of atropine inhalation

MicroDose Therapeutx Inc. (formerly MicroDose Technologies) today announced that it has initiated a Phase I study at the University of Pittsburgh Medical Center with atropine sulfate delivered from the MicroDose proprietary dry powder inhaler (DPI). The study is a further step in the development program for an atropine inhaler to treat nerve agent poisoning in military and civil defense applications.

24 Sep 2009

It is possible to reduce the risk of HIV infection with a vaccine: AVAC

"Today marks an historic milestone in the search for an AIDS vaccine; we now have evidence that it is possible to reduce the risk of HIV infection with a vaccine," said AVAC executive director Mitchell Warren, reacting to the results of the first AIDS vaccine trial to ever show efficacy at preventing HIV. "It will take time and resources to fully analyze, understand and validate the data, but there is little doubt that this finding will energize and redirect the AIDS vaccine field as all of us begin the hard work to translate this landmark result into true public health benefit."

24 Sep 2009

Results of Phase III clinical trial of HIV vaccine released

A Phase III clinical trial involving more than 16,000 adult volunteers in Thailand has demonstrated that an investigational HIV vaccine regimen was safe and modestly effective in preventing HIV infection. According to final results released by the trial sponsor, the U.S. Army Surgeon General, the prime boost combination of ALVAC(R)( )HIV and AIDSVAX(R) B/E( )lowered the rate of HIV infection by 31.2% compared with placebo.

24 Sep 2009

Morphotek receives NIAID grant to develop human mAb therapies against staphylococcal-derived pathogens

Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced today that it was awarded $843,289 in funding from the National Institutes of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to support the development of human monoclonal antibody (mAb) therapies against staphylococcal-derived toxin(s).

23 Sep 2009

Dust Alert sensor to monitor quality of air

Worried that dust from a nearby construction zone will harm your family's health? A new Tel Aviv University tool could either confirm your suspicions or better yet, set your mind at rest.

23 Sep 2009

Chan calls for additional H1N1 vaccines for poor countries during WHO Asia-Pacific regional meeting

During the WHO Asia-Pacific regional meeting Monday, WHO Director-General Margaret Chan discussed the organization's efforts to ensure that poor nations have access to H1N1 vaccines, VOA News reports (Bayron, 9/21).

23 Sep 2009

Government orders additional H1N1 vaccine

Associated Press/Boston Globe reports that on Monday, "the United States ordered more swine flu vaccine, bringing its eventual total to 251 million doses, up from the long-planned 195 million doses.

23 Sep 2009

Emissary Capital begins investment research coverage on Sinobiopharma

Emissary Capital Group, Inc. has initiated investment research coverage on Sinobiopharma, Inc. (OTC Bulletin Board: SNBP) with a Buy rating and target price of $1.00-$1.25.

22 Sep 2009

Results from a trial testing a 2009 H1N1 influenza vaccine in children look promising

Early results from a trial testing a 2009 H1N1 influenza vaccine in children look promising, according to the trial sponsor, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

22 Sep 2009

Biochemists are developing a new system to better understand antibiotic resistance

Rice University biochemists are developing a system of "evolutionary forecasting" to better understand the mechanisms of antibiotic resistance.

22 Sep 2009

NIAID awards DOR BioPharma a $9M grant to develop thermostable and rapidly acting vaccines

DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that it has been awarded an approximate $9.4 Million grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH).

21 Sep 2009

NIAID awards Antigen Discovery a Phase II STTR grant for Chlamydia vaccine development

Antigen Discovery, Inc. ("ADi", formerly ImmPORT Therapeutics, Inc.), a leading biotech company in high throughput antigen and biomarker discovery, announced today that the Company was awarded a Phase II STTR from the National Institute of Allergy and Infectious Diseases (NIAID) under the American Recovery and Reinvestment Act (ARRA) of 2009.

21 Sep 2009

Study reveals that allergies are a major health issue in Sweden

Asthma, nasal symptoms and eczema is a major public health problem in Sweden, not least among young people. Half of all teenagers are affected in Västra Götaland County in West Sweden.

21 Sep 2009

Health experts to discuss innovative breakthroughs to solve health issues in poor communities

New ideas, systems and technologies are emerging to solve numerous health challenges facing the world’s poorest communities. Some of the foremost experts on global health will discuss these and the prospects for health breakthroughs in the developing world at a media briefing at the Conrad N. Hilton Humanitarian Symposium at 2:30 pm on Monday, September 21.

19 Sep 2009

Pharmacyclics announces financial results for fourth quarter and FY 2009

Pharmacyclics, Inc. today reported financial results for its fourth quarter and fiscal year ended June 30, 2009. During the fourth quarter of fiscal 2009 Pharmacyclics incurred a GAAP net loss of $5.4 million, or $0.20 per share, compared to a net loss of $4.6 million, or $0.18 per share for the fourth quarter of fiscal 2008.

18 Sep 2009

New vaccine may prove effective against urinary tract infections

University of Michigan scientists have made an important step toward what could become the first effective vaccine to prevent urinary tract infections, if the robust immunity achieved in mice can be reproduced in humans.

18 Sep 2009

NIH to fund grants for epigenetic research

The National Institutes of Health announced today that it will fund 22 grants on genome-wide studies of how epigenetic changes -- chemical modifications to genes that result from diet, aging, stress, or environmental exposures -- define and contribute to specific human diseases and biological processes.

17 Sep 2009

Study: Antiretroviral drugs may prevent HIV infection in women

Hopeful that some of the same antiretroviral (ARV) drugs used to treat HIV infection can also prevent it, researchers from the Microbicide Trials Network have enrolled the first participants into a new, large-scale clinical trial testing two approaches of the strategy in women.

17 Sep 2009

Allergy News and Research

Further Reading

Combination drug to limit the dangerous side effects of morphine

La Jolla Institute scientist Hilde Cheroutre earns the 2009 NIH Director's Pioneer Award

MicroDose initiates Phase 1 clinical trial investigating the pharmacokinetics of atropine inhalation

It is possible to reduce the risk of HIV infection with a vaccine: AVAC

Results of Phase III clinical trial of HIV vaccine released

Morphotek receives NIAID grant to develop human mAb therapies against staphylococcal-derived pathogens

Dust Alert sensor to monitor quality of air

Chan calls for additional H1N1 vaccines for poor countries during WHO Asia-Pacific regional meeting

Government orders additional H1N1 vaccine

Emissary Capital begins investment research coverage on Sinobiopharma

Results from a trial testing a 2009 H1N1 influenza vaccine in children look promising

Biochemists are developing a new system to better understand antibiotic resistance

NIAID awards DOR BioPharma a $9M grant to develop thermostable and rapidly acting vaccines

NIAID awards Antigen Discovery a Phase II STTR grant for Chlamydia vaccine development

Study reveals that allergies are a major health issue in Sweden

Health experts to discuss innovative breakthroughs to solve health issues in poor communities

Pharmacyclics announces financial results for fourth quarter and FY 2009

New vaccine may prove effective against urinary tract infections

NIH to fund grants for epigenetic research

Study: Antiretroviral drugs may prevent HIV infection in women

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News